VIDEO: ‘Significant promise’ for first molecularly targeted agent in MDS
Click Here to Manage Email Alerts
CHICAGO — In a video interview, Healio spoke with David Andrew Sallman, MD, myeloid section head at Moffitt Cancer Center, about using targeted therapy in patients with myelodysplastic syndrome at ASCO Annual Meeting.
According to Sallman, over 70% of patients with IDH1-mutant relapsed or refractory MDS in a phase 1 study are responding to ivosidenib (Tibsovo, Agios Pharmaceuticals), a first-in-class IDH1 inhibitor, with patients having durations of response over 5 years.
“The response rates are somewhat better than even [acute myeloid leukemia] populations. It argues that if you utilize these medications earlier, that’s potentially the best window [and] it may lead to the ultimate best outcomes for our patients,” Sallman said. “It really offers potentially significant promise for our first molecularly targeted agent in MDS.”
Collapse
Sallman DA, et al. Abstract 7053. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Read more about
Click Here to Manage Email Alerts